Sugi Predict

Sugi Predict / Compounds / SCHEMBL350358

SCHEMBL350358

SCHEMBL350358

CN[C@@H](CCCCNC(=N)N)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 9/20 0.43
▸ ALOX15 P16050 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NOD1 Q9Y239 1/20 0.36
▸ SIRT6 Q8N6T7 1/20 0.35
▸ SIRT1 Q96EB6 1/20 0.35
▸ TLR2 O60603 1/20 0.35
▸ SIRT5 Q9NXA8 1/20 0.35
▸ NPY4R P50391 3/20 0.35
▸ NPY1R P25929 2/20 0.35
▸ NPY2R P49146 2/20 0.35
▸ NPY5R Q15761 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29888878 1.00 FOLH1 (0.43) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL8663352 1.00 FOLH1 (0.43) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
Acetic Acid SCHEMBL4407896 0.97 FOLH1 (0.44) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL93473 0.95 FOLH1 (0.38) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL17769024 0.95 FOLH1 (0.38) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL93472 0.95 FOLH1 (0.38) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
SCHEMBL162756 0.95 FOLH1 (0.38) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
Hydrochloric Acid SCHEMBL1578565 0.93 FOLH1 (0.37) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
Hydrochloric Acid SCHEMBL7367067 0.93 FOLH1 (0.37) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2
Hydrochloric Acid SCHEMBL974818 0.93 FOLH1 (0.37) FOLH1ALOX15SMN1; SMN2MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119158034-A Bicyclic peptide ligands specific for conjugated protein-4 拜斯科技术开发有限公司 2024-12-20 — — CN claimed
EP-4464715-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 BicycleTx Limited (GB) 2024-11-20 — — EP claimed
US-20240209026-A1 A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS PROTAGONIST THERAPEUTICS, INC. (US) 2024-06-27 — — US claimed
US-20220162261-A1 NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS PROTAGONIST THERAPEUTICS, INC. 2022-05-26 — — US claimed
EP-3810169-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 BicycleTX Limited (GB) 2021-04-28 — — EP claimed
CN-112601539-A Bicyclic peptide ligands specific for bindin-4 拜斯科技术开发有限公司 2021-04-02 — — CN claimed
WO-2019243832-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 BICYCLETX LIMITED (GB) 2019-12-26 — — WO claimed
US-7855325-B2 Use of nitric oxide modulators in Agrobacterium-mediated plant transformation MONSANTO TECHNOLOGY LLC (US) 2010-12-21 — — US claimed
US-20080274547-A1 USE OF NITRIC OXIDE MODULATORS IN AGROBACTERIUM-MEDIATED PLANT TRANSFORMATION MONSANTO TECHNOLOGY LLC 2008-11-06 — — US claimed
US-7388126-B2 Such as NG-monomethyl-L-arginine, monoacetate salt; corn plants MONSANTO TECHNOLOGY LLC (US) 2008-06-17 — — US claimed
US-12459974-B2 Bicyclic peptide ligands specific for Nectin-4 BICYCLETX LIMITED (GB) 2025-11-04 — — US disclosed
US-20250263438-A9 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 BICYCLETX LIMITED (GB) 2025-08-21 — — US disclosed
EP-4588934-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 BicycleTX Limited (GB) 2025-07-23 — — EP disclosed
WO-2025069022-A1 IMMUNOMODULATING PEPTIDES AND USES THEREOF HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2025-04-03 — — WO disclosed
US-20250066421-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 BICYCLETX LIMITED (GB) 2025-02-27 — — US disclosed
EP-0270214-A2 Vasopressin antagonists SMITHKLINE BEECHAM CORPORATION (US) 1988-06-08 — — EP disclosed
US-4724229-A Arg-arg-arg-vasopressin antagonists SMITHKLINE BECKMAN CORPORATION (US) 1988-02-09 — — US disclosed
US-4717715-A CYCLIC OCTAPEPTIDE DIURETICS SMITHKLINE BECKMAN CORPORATION (US) 1988-01-05 — — US disclosed
EP-0231077-A2 Polypeptide compounds SMITHKLINE BECKMAN CORPORATION (US) 1987-08-05 — — EP disclosed
EP-0206730-A2 Vasopressin antagonists SMITHKLINE BECKMAN CORPORATION (US) 1986-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459974-B2 Bicyclic peptide ligands specific for Nectin-4 NECTIN4, VCAM1, SIGLEC7 FOLH1 956/4885ALOX15 4565/4885SMN1; SMN2 2834/4885
US-20250263438-A9 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 NECTIN4, VCAM1, SIGLEC7 FOLH1 956/4885ALOX15 4565/4885SMN1; SMN2 2834/4885
US-20240209026-A1 A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS EPCAM, ANXA7, GRB7 FOLH1 1606/4885ALOX15 3677/4885SMN1; SMN2 4579/4885
US-20220162261-A1 NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS EPCAM, VCAM1, ITGB7 FOLH1 2497/4885ALOX15 3859/4885SMN1; SMN2 3964/4885
US-20250066421-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 NECTIN4, VCAM1, SIGLEC7 FOLH1 956/4885ALOX15 4565/4885SMN1; SMN2 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.